Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioGend Therapeutics Co (6733) Fair Value & Analysis

Healthcare · TW · Market cap 3.4B TWD

Price24.00 TWD
Fair Value16.57 TWD
Upside-31.0%
Quality92/100
Evidence: Low Range 12.43 TWD – 20.72 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

BioGend Therapeutics Co (6733) currently trades at 24.00 TWD, while our model-based Fair Value estimate is 16.57 TWD — implying the stock looks roughly 31.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is BioGend Therapeutics Co (6733) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 16.57 TWD versus a price of 24.00 TWD — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6733?
Our 21-model fair value for BioGend Therapeutics Co is 16.57 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 24.00 TWD.
What is the quality score of 6733?
BioGend Therapeutics Co has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.